{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:38:47Z","timestamp":1792625927097,"version":"4.5.0"},"reference-count":14,"publisher":"MyJove Corporation","issue":"160","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/60832","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T20:00:31Z","timestamp":1591905631000},"source":"Crossref","is-referenced-by-count":3,"title":["Delivery of Modified mRNA in a Myocardial Infarction Mouse Model"],"prefix":"10.3791","author":[{"given":"Keerat","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishat","family":"Sultana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Hadas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Magadum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Tofael Kabir","family":"Sharkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chepurko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Zangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/hum.2004.15.1157","type":"journal-article","article-title":"The innate immune response to adenovirus vectors","volume":"15","author":"Muruve","year":"2004","unstructured":"Muruve, D. A. The innate immune response to adenovirus vectors. Human Gene Therapy. 15 (12), 1157-1166 (2004).","journal-title":"Human Gene Therapy"},{"issue":"17","key":"ref2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","type":"journal-article","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","unstructured":"Donsante, A. et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Therapy. 8 (17), 1343-1346 (2001).","journal-title":"Gene Therapy"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","type":"journal-article","article-title":"Humoral Immune Response to AAV","volume":"4","author":"Calcedo","year":"2013","unstructured":"Calcedo, R., Wilson, J. M. Humoral Immune Response to AAV. Frontiers in Immunology. 4, 341 (2013).","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/eji.200636617","type":"journal-article","article-title":"Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides","volume":"36","author":"Diebold","year":"2006","unstructured":"Diebold, S. S. et al. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. European Journal of Immunology. 36 (12), 3256-3267 (2006).","journal-title":"European Journal of Immunology"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","type":"journal-article","article-title":"mRNA-Based Protein Replacement Therapy for the Heart","volume":"27","author":"Magadum","year":"2019","unstructured":"Magadum, A., Kaur, K., Zangi, L. mRNA-Based Protein Replacement Therapy for the Heart. Molecular Therapy. 27 (4), 785-793 (2019).","journal-title":"Molecular Therapy"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","type":"journal-article","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","unstructured":"Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy. 16 (11), 1833-1840 (2008).","journal-title":"Molecular Therapy"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.omtm.2019.07.006","type":"journal-article","article-title":"Optimizing Modified mRNA In Vitro Synthesis Protocol for Heart Gene Therapy","volume":"14","author":"Hadas","year":"2019","unstructured":"Hadas, Y. et al. Optimizing Modified mRNA In Vitro Synthesis Protocol for Heart Gene Therapy. Molecular Therapy- Methods and Clinical Development. 14, 300-305 (2019).","journal-title":"Molecular Therapy- Methods and Clinical Development"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ymthe.2017.03.016","type":"journal-article","article-title":"Optimizing Cardiac Delivery of Modified mRNA","volume":"25","author":"Sultana","year":"2017","unstructured":"Sultana, N. et al. Optimizing Cardiac Delivery of Modified mRNA. Molecular Therapy. 25 (6), 1306-1315 (2017).","journal-title":"Molecular Therapy"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","type":"journal-article","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","unstructured":"Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nature Biotechnology. 31 (10), 898-907 (2013).","journal-title":"Nature Biotechnology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","type":"journal-article","article-title":"Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine","volume":"9","author":"Carlsson","year":"2018","unstructured":"Carlsson, L. et al. Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine. Molecular Therapy Methods Clinical Development. 9, 330-346 (2018).","journal-title":"Molecular Therapy Methods Clinical Development"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/mp5006239","type":"journal-article","article-title":"Synthetic chemically modified mRNA-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction","volume":"12","author":"Huang","year":"2015","unstructured":"Huang, C. L. et al. Synthetic chemically modified mRNA-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction. Molecular Pharmaceutics. 12 (3), 991-996 (2015).","journal-title":"Molecular Pharmaceutics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.omtn.2018.08.021","type":"journal-article","article-title":"Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration","volume":"13","author":"Magadum","year":"2018","unstructured":"Magadum, A. et al. Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration. Molecular Therapy - Nucleic Acids. 13, 133-143 (2018).","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4939-6588-5_8","type":"journal-article","article-title":"Synthesis of Modified mRNA for Myocardial Delivery","volume":"1521","author":"Kondrat","year":"2017","unstructured":"Kondrat, J., Sultana, N., Zangi, L. Synthesis of Modified mRNA for Myocardial Delivery. Methods in Molecular Biology. 1521, 127-138 (2017).","journal-title":"Methods in Molecular Biology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41467-019-08852-4","type":"journal-article","article-title":"Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes","volume":"10","author":"Gan","year":"2019","unstructured":"Gan, L. M. et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nature Communication. 10 (1), 871 (2019).","journal-title":"Nature Communication"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/60832\/delivery-of-modified-mrna-in-a-myocardial-infarction-mouse-model","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:56:41Z","timestamp":1792623401000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/60832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":14,"journal-issue":{"issue":"160","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3791\/60832","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]}}}